Study of left ventricular myocardial hypertrophy in rats with experimental type 2 diabetes and following administration of L-arginine and N-acetyl-L-cysteine

Authors

DOI:

https://doi.org/10.14739/2310-1210.2026.4.363959

Keywords:

diabetes mellitus type 2, remodeling, myocardium, left ventricle, morphometry, L-arginine, N-acetyl-L-cysteine, rats

Abstract

Aim. To evaluate the morphometric parameters of left ventricular myocardial hypertrophy in rats with experimental type 2 diabetes mellitus (DM2) and with L-arginine and N-acetyl-L-cysteine administration.

Materials and methods. The study was conducted on 42 male Wistar rats. DM2 was modeled by an 8-week high-fat diet followed by the administration of streptozotocin (30 mg/kg). The animals were divided into a control group and three DM2subgroups: without amino acids, with L-arginine administration and with N-acetyl-L-cysteine administration for 2 weeks dissolved in drinking water (1.5 g/kg/l). Histological staining with hematoxylin and eosin was performed. Morphometrically, the mean area and minimum Feret diameter of cardiomyocytes (CMC), total CMC area, mean and total nuclear area were assessed using ImageJ with subsequent calculation of the nuclear-cytoplasmic ratio (NCR) and cell density per 1 mm2 of the tissue.

Results. The development of DM2 led to pronounced hypertrophy: the mean area of CMC increased by 28 %, and minimum Feret diameter by 23 % compared to the control. An increase in mean nuclear area of 29 % was observed, alongside a decrease in NCR by 12 % and cell density by 15 %. Administration of L-arginine to DM2 animals contributed to a decrease in mean CMC area by 8 % and restoration of cell density by 18 % compared to the non-supplemented DM2 group. N-acetyl-L-cysteine demonstrated a more pronounced effect compared to L-arginine, with statistically significant reductions in mean nuclear area (14 %) and increases in CMC cytoplasmic area (4 %) and cell density (12 %), p ˂ 0.05.

Conclusions. The development of experimental type 2 diabetes mellitus leads to pronounced hypertrophic structural reorganization of the left ventricular myocardium with impairment of the nuclear-to-cytoplasmic ratio and reduced cardiomyocyte density. Administration of L-arginine exerts a cardioprotective effect, manifested by attenuation of diabetes-induced hypertrophic remodeling, reduction of the nuclear-to-cytoplasmic ratio, and increased cell density per 1 mm2 of the tissue. Administration of N-acetyl-L-cysteine demonstrates a more pronounced effect compared to L-arginine, optimizing the balance between the nuclear and cytoplasmic compartments of the myocardial parenchyma, successfully restoring histological cell density per 1 mm2 of the tissue.

Author Biography

M. I. Isachenko, Zaporizhzhia State Medical and Pharmaceutical University

MD, PhD, Associate Professor of the Department of Pathological Physiology with the Course of Normal Physiology

References

  1. Galis P, Bartosova L, Farkasova V, Bartekova M, Ferenczyova K, Rajtik T. Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy. Front Endocrinol (Lausanne). 2024;15:1451100. doi: https://doi.org/10.3389/fendo.2024.1451100
    | |
  2. Marino F, Salerno N, Scalise M, Salerno L, Torella A, Molinaro C, et al. Streptozotocin-Induced Type 1 and 2 Diabetes Mellitus Mouse Models Show Different Functional, Cellular and Molecular Patterns of Diabetic Cardiomyopathy. Int J Mol Sci. 2023;24(2):1132. doi: https://doi.org/10.3390/ijms24021132
    | |
  3. Dhar A, Venkadakrishnan J, Roy U, Vedam S, Lalwani N, Ramos KS, et al. A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy. Ther Adv Cardiovasc Dis. 2023;17:17539447231210170. doi: https://doi.org/10.1177/17539447231210170
    | |
  4. Zhou D, Yang Y, Chen J, Zhou J, He J, Liu D, et al. N-acetylcysteine Protects Against Myocardial Ischemia-Reperfusion Injury Through Anti-ferroptosis in Type 1 Diabetic Mice. Cardiovasc Toxicol. 2024;24(5):481-98. doi: https://doi.org/10.1007/s12012-024-09852-7
    | |
  5. Altındağ F, İgit T. Does N-acetylcysteine alleviate diabetic cardiomyopathy in diabetic rats. Neuro-Cell Mol Res. 2025;2(2):34-8. doi: https://doi.org/10.5281/zenodo.16986801
  6. Kolesnyk YM, Isachenko MI. [Modeling insulin resistance in Wistar rats induced by a combined high-fat diet as a predictor of type 2 diabetes (experimental phase 1 study)]. Pathologia. 2025;22(1):5-11. Ukrainian. doi: https://doi.org/10.14739/2310-1237.2025.1.314277
    |
  7. Isachenko MI, Kolesnyk YM. [Assessment of changes in carbohydrate metabolism parameters in rats with experimental diabetes mellitus of different origins under L-arginine and N-acetyl-L-cysteine administration]. Pathologia. 2025;22(2):93-9. Ukrainian. doi: https://doi.org/10.14739/2310-1237.2025.2.337017
    |
  8. Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17(9):585-607. doi: https://doi.org/10.1038/s41569-020-0339-2
    | |
  9. Thakur MR, Tupe RS. l-Arginine: A multifaceted regulator of diabetic cardiomyopathy. Biochem Biophys Res Commun. 2025;761:151720. doi: https://doi.org/10.1016/j.bbrc.2025.151720
    | |
  10. Li W, Li W, Leng Y, Xiong Y, Xue R, Chen R, et al. Mechanism of N-acetylcysteine in alleviating diabetic myocardial ischemia reperfusion injury by regulating PTEN/Akt pathway through promoting DJ-1. Biosci Rep. 2020;40(6):BSR20192118. doi: https://doi.org/10.1042/BSR20192118
    | |

Additional Files

Published

2026-07-08

How to Cite

1.
Isachenko MI. Study of left ventricular myocardial hypertrophy in rats with experimental type 2 diabetes and following administration of L-arginine and N-acetyl-L-cysteine. Zaporozhye Medical Journal [Internet]. 2026Jul.8 [cited 2026Jul.13];28(4):334-8. Available from: https://zmj.zsmu.edu.ua/article/view/363959

Issue

Section

Original research